Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Home - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 722272 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Printer Friendly
PDF Brochure
Send to Friend
Enquire before Buying
| More
Electronic (PDF)Add to Basket
EnterprisewideAdd to Basket



Pipeline Insight: Hematological Malignancies - Pursuit For The Next Blockbuster Intensifies
Datamonitor, March 2007, Pages: 374


  Description  
  Table of Contents  
    
    
    
   
 Enquire before Buying  
 Send to a Friend  

Unmet needs across the hematological malignancies remain high, with most traditional therapies conferring low levels of specificity and high toxicity.

Pipeline candidates classified as molecular targeted therapies, cytotoxic therapies and immunotherapeutic agents, may offer attractive therapeutic additions and our insight into their clinical and commercial potential is provided.

Scope of this title:

Research and analysis of the hematological malignancies pipeline with in-depth clinical and commercial assessment of Phase III candidates

Seven major pharmaceutical market sales forecasts to 2016 for key pipeline candidates incorporating product specific assumptions and events

Segmentation and examination of product pipeline by developmental phase, class, indication and developer

Insight and analysis of the hematological malignancies market potential including commercial opportunity and disease epidemiology

Highlights of this title:

180 different pipeline candidates have been identified of which 22 are in late-phase development. These existing candidates have a forecast sales potential of up to $3.61 billion in the seven major pharmaceutical markets by 2016. Agents holding strong commercial potential include Novartis Gleevec-follow-on, Tasigna (nilotinib), and Genzymes already approved purine analog Clolar (clofarabine) which is in development for acute myeloid leukemia. Other notable candidates include the anti-idiotype therapeutic vaccines and Biogen Idecs anti-CD23 MAb, lumiliximab. Over 50% of the products are being investigated in acute and/or chronic leukemia. However, as an individual hematological subtype, NHL attracts the greatest attention from developers with 53 (29%) products in the pipeline despite the malignancy being comparatively well served by existing treatment regimens.

Reasons to order your copy:

Acquire a detailed appreciation and impartial perspective of the entire hematological malignancies developmental pipeline
Identify the key products in late-phase development based on sales forecasts to 2016 and ours drug assessment methodology
Consider, assess and react to opportunities and risks influencing the future potential of products in the hematological malignancies pipeline



Customers who bought this item also bought

Hematological Malignancies: Companies Target Niche Indications to Facilitate Market Entry

Pipeline Insight: Hematological Malignancies - Targeted Treatments And Immunotherapy Infuse New Blood

Global Pipeline Review & Analysis of Hematological Malignancies

Analytical Tool - Hematological Cancers

Prospects for the Phase III Bapineuzumab Trial

Pipeline Insight: Molecular Targeted Cancer Therapies - More Pipeline Activity, Less Product Differentiation

Hematological Cancers - A Therapeutic & Competitive Insight

TNFerade Phase III Clinical Trial Results Call - GenVec, Inc., - Earnings Transcript

Trial TRAX - Multiple Sclerosis - Clinical Trial Monitoring Brief

Inhalers Clinical Trial Analysis

Antibody drug conjugates for cancer treatment: Clinical Trial Pipeline

Pharmacogenomics for Clinical Use and in Drug Development



Top of page


   All rights reserved. � Copyright 2009 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster


Research and Markets RSS Feeds